| Symbol | KEYBF |
|---|---|
| Name | KEYMED BIOSCIENCES INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | - |
| Address | China HK Room 1701, Lippo Centre Tower 2 |
| Telephone | — |
| Fax | — |
| — | |
| Website | https://en.keymedbio.com/ |
| Incorporation | — |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | NOT AVAILABLE |
| Reporting Status | International Reporting: Hong Kong Stock Exchange |
| CIK | — |
| Description | Keymed Biosciences Inc is a China-based biotechnology company. The Company focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The Company has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Companys main products include CM310, CM326 and CMG901. Additional info from OTC: |
No news found.